These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15586623)

  • 1. Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism.
    Haas S
    Drugs; 2004; 64 Suppl 1():7-16. PubMed ID: 15586623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP
    Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ximelagatran.
    Choudhury A; Goyal D; Lip GY
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New blood thinner offers first potential alternative in 50 years: ximelagatran.
    Nutescu EA; Helgason CM; Briller J; Schwertz DW
    J Cardiovasc Nurs; 2004; 19(6):374-83. PubMed ID: 15529058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran.
    Eriksson H
    Drugs; 2004; 64 Suppl 1():37-46. PubMed ID: 15586626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
    Agnelli G
    Drugs; 2004; 64 Suppl 1():47-52. PubMed ID: 15586627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N
    Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation: the present and future.
    Van Aken H; Bode C; Darius H; Diehm C; Encke A; Gulba DC; Haas S; Hacke W; Puhl W; Quante M; Riess H; Scharf R; Schellong S; Schrör T; Schulte KL; Tebbe U
    Clin Appl Thromb Hemost; 2001 Jul; 7(3):195-204. PubMed ID: 11441979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral direct thrombin inhibitors in clinical development.
    Gustafsson D
    J Intern Med; 2003 Oct; 254(4):322-34. PubMed ID: 12974871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition.
    Kereiakes DJ
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S4-11. PubMed ID: 15619615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran--a promising new drug in thromboembolic disorders.
    Petersen P
    Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active direct thrombin inhibitors.
    Weitz J
    Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ximelagatran: direct thrombin inhibitor.
    Ho SJ; Brighton TA
    Vasc Health Risk Manag; 2006; 2(1):49-58. PubMed ID: 17319469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.